Medika d.d., together with its subsidiaries, engages in the wholesale and retail distribution of pharmaceutical products in the Republic of Croatia.
Price History & Performance
|Historical stock prices|
|Current Share Price||Kn26,000.00|
|52 Week High||Kn16,000.00|
|52 Week Low||Kn26,400.00|
|1 Month Change||13.04%|
|3 Month Change||23.81%|
|1 Year Change||52.94%|
|3 Year Change||61.49%|
|5 Year Change||62.50%|
|Change since IPO||229.11%|
Recent News & Updates
Statutory Profit Doesn't Reflect How Good Medika d.d's (ZGSE:MDKA) Earnings Are
The subdued stock price reaction suggests that Medika d.d.'s ( ZGSE:MDKA ) strong earnings didn't offer any surprises...
|MDKA||HR Healthcare||HR Market|
Return vs Industry: MDKA exceeded the HR Healthcare industry which returned 13.2% over the past year.
Return vs Market: MDKA exceeded the HR Market which returned 14.3% over the past year.
Stable Share Price: Insufficient data to determine MDKA's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine MDKA's volatility change over the past year.
About the Company
Medika d.d., together with its subsidiaries, engages in the wholesale and retail distribution of pharmaceutical products in the Republic of Croatia. The company primarily sells, stores, and distributes human and veterinary drugs, medicinal products, equipment and dental supplies, dietetic, cosmetic, hygienic, and other products. It serves pharmacies, healthcare facilities, hospitals, health centers, outpatient facilities, doctor’s offices, wholesalers, and specialized stores; and dental practices, veterinary clinics, and medical centers, as well as other customers, including herbal pharmacies, companies, optics, and other.
Medika d.d Fundamentals Summary
|MDKA fundamental statistics|
Is MDKA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDKA income statement (TTM)|
|Cost of Revenue||Kn3.67b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 28, 2021
|Earnings per share (EPS)||3.19k|
|Net Profit Margin||2.32%|
How did MDKA perform over the long term?See historical performance and comparison
5.4%Current Dividend Yield
Is Medika d.d undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MDKA (HRK26000) is trading below our estimate of fair value (HRK891451.29)
Significantly Below Fair Value: MDKA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MDKA is good value based on its PE Ratio (8.1x) compared to the European Healthcare industry average (25.3x).
PE vs Market: MDKA is good value based on its PE Ratio (8.1x) compared to the HR market (16.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDKA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDKA is good value based on its PB Ratio (1.3x) compared to the XE Healthcare industry average (2.3x).
How is Medika d.d forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medika d.d has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Medika d.d performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDKA has high quality earnings.
Growing Profit Margin: MDKA's current net profit margins (2.3%) are higher than last year (1.7%).
Past Earnings Growth Analysis
Earnings Trend: MDKA's earnings have grown by 9.6% per year over the past 5 years.
Accelerating Growth: MDKA's earnings growth over the past year (42.2%) exceeds its 5-year average (9.6% per year).
Earnings vs Industry: MDKA earnings growth over the past year (42.2%) exceeded the Healthcare industry 31.2%.
Return on Equity
High ROE: MDKA's Return on Equity (15.8%) is considered low.
How is Medika d.d's financial position?
Financial Position Analysis
Short Term Liabilities: MDKA's short term assets (HRK1.9B) exceed its short term liabilities (HRK1.8B).
Long Term Liabilities: MDKA's short term assets (HRK1.9B) exceed its long term liabilities (HRK125.5M).
Debt to Equity History and Analysis
Debt Level: MDKA's debt to equity ratio (43.5%) is considered high.
Reducing Debt: MDKA's debt to equity ratio has reduced from 94.1% to 43.5% over the past 5 years.
Debt Coverage: MDKA's debt is well covered by operating cash flow (143.4%).
Interest Coverage: MDKA's interest payments on its debt are well covered by EBIT (89.9x coverage).
What is Medika d.d current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MDKA's dividend (5.38%) is higher than the bottom 25% of dividend payers in the HR market (1.84%).
High Dividend: MDKA's dividend (5.38%) is in the top 25% of dividend payers in the HR market (4.12%)
Stability and Growth of Payments
Stable Dividend: MDKA has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: MDKA's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (43.9%), MDKA's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Jasminko Herceg, Dipl. Oec, serves as a President of Management Board at Medika, d.d
Experienced Board: MDKA's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.2%.
Medika d.d.'s employee growth, exchange listings and data sources
- Name: Medika d.d.
- Ticker: MDKA
- Exchange: ZGSE
- Founded: 1922
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: Kn752.804m
- Shares outstanding: 28.95k
- Website: https://www.medika.hr
Number of Employees
- Medika d.d.
- Capraska 1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 16:07|
|End of Day Share Price||2021/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.